Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Human Papillomavirus Protein E7 (E7) - Overview Human Papillomavirus Protein E7 (E7) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development Abion Inc Advaxis Inc Bioleaders Corp BioNTech AG Cancer Research Technology Ltd Etubics Corp Formune SL Genexine Inc Hookipa Biotech AG iBio Inc Immunovaccine Inc Inovio Pharmaceuticals Inc MedImmune LLC Selecta Biosciences Inc Touchlight Genetics Ltd Transgene SA VLPbio Human Papillomavirus Protein E7 (E7) - Drug Profiles ABN-301 - Drug Profile Product Description Mechanism Of Action R&D Progress Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress axalimogene filolisbac - Drug Profile Product Description Mechanism Of Action R&D Progress axalimogene filolisbac second generation - Drug Profile Product Description Mechanism Of Action R&D Progress BLSILSB-710c - Drug Profile Product Description Mechanism Of Action R&D Progress BVAC-C - Drug Profile Product Description Mechanism Of Action R&D Progress CerviVax - Drug Profile Product Description Mechanism Of Action R&D Progress CUE-101 - Drug Profile Product Description Mechanism Of Action R&D Progress CUE-201 - Drug Profile Product Description Mechanism Of Action R&D Progress DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile Product Description Mechanism Of Action R&D Progress DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile Product Description Mechanism Of Action R&D Progress DPXE-7 - Drug Profile Product Description Mechanism Of Action R&D Progress EDA-HPVE7 - Drug Profile Product Description Mechanism Of Action R&D Progress Enzymes to Inhibit HPV E6 and E7 for Cervical Intraepithelial Neoplasia - Drug Profile Product Description Mechanism Of Action R&D Progress Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress ETBX-041 - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress GLBL-101c - Drug Profile Product Description Mechanism Of Action R&D Progress GX-188E - Drug Profile Product Description Mechanism Of Action R&D Progress HB-201 - Drug Profile Product Description Mechanism Of Action R&D Progress human papillomavirus [Serotype 16] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress human papillomavirus [serotypes 16] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress human papillomavirus vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress INO-3106 - Drug Profile Product Description Mechanism Of Action R&D Progress MEDI-0457 - Drug Profile Product Description Mechanism Of Action R&D Progress PVX-01 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Vector Vaccine to Target Human Papillomavirus Protein E7 for HPV Associated Cervical Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress SEL-701 - Drug Profile Product Description Mechanism Of Action R&D Progress TA-CIN - Drug Profile Product Description Mechanism Of Action R&D Progress TG-4001 - Drug Profile Product Description Mechanism Of Action R&D Progress Tricurin - Drug Profile Product Description Mechanism Of Action R&D Progress TTFC-E7SH - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress VGX-3100 - Drug Profile Product Description Mechanism Of Action R&D Progress Vvax-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Human Papillomavirus Protein E7 (E7) - Dormant Products Human Papillomavirus Protein E7 (E7) - Discontinued Products Human Papillomavirus Protein E7 (E7) - Product Development Milestones Featured News & Press Releases Feb 13, 2018: Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union Feb 12, 2018: Advaxis Announces Publication Of Phase 2 Results Evaluating Axalimogene Filolisbac For The Treatment Of Recurrent Metastatic Cervical Cancer In The International Journal Of Gynecological Cancer Jan 29, 2018: Data Highlighting Advaxis Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies Jan 08, 2018: Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2 Dec 05, 2017: Cue Biopharma Announces Appointment of Colin Sandercock as Senior Vice President and General Counsel Nov 29, 2017: Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy Nov 27, 2017: Inovio Pharmaceuticals Provides Update on Cancer Drug Candidate INO-3112 Nov 10, 2017: Inovio Pharmaceuticals Presents data on MEDI0457 at Society for Immunotherapy of Cancer Conference Sep 19, 2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers Jul 13, 2017: Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders Jun 26, 2017: Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 Jun 19, 2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer May 18, 2017: Advaxis to Host Investor & Analyst Day on June 12 May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Companies, H1 2018 (Contd..1) Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Products under Development by Companies, H1 2018 (Contd..2), H1 2018 Products under Development by Companies, H1 2018 (Contd..3), H1 2018 Products under Development by Companies, H1 2018 (Contd..4), H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Abion Inc, H1 2018 Pipeline by Advaxis Inc, H1 2018 Pipeline by Bioleaders Corp, H1 2018 Pipeline by BioNTech AG, H1 2018 Pipeline by Cancer Research Technology Ltd, H1 2018 Pipeline by Etubics Corp, H1 2018 Pipeline by Formune SL, H1 2018 Pipeline by Genexine Inc, H1 2018 Pipeline by Hookipa Biotech AG, H1 2018 Pipeline by iBio Inc, H1 2018 Pipeline by Immunovaccine Inc, H1 2018 Pipeline by Inovio Pharmaceuticals Inc, H1 2018 Pipeline by MedImmune LLC, H1 2018 Pipeline by Selecta Biosciences Inc, H1 2018 Pipeline by Touchlight Genetics Ltd, H1 2018 Pipeline by Transgene SA, H1 2018 Pipeline by VLPbio, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Top 10 Molecule Types, H1 2018 Number of Products by Stage and Top 10 Molecule Types, H1 2018

Abion Inc Advaxis Inc Bioleaders Corp BioNTech AG Cancer Research Technology Ltd Etubics Corp Formune SL Genexine Inc Hookipa Biotech AG iBio Inc Immunovaccine Inc Inovio Pharmaceuticals Inc MedImmune LLC Selecta Biosciences Inc Touchlight Genetics Ltd Transgene SA VLPbio